This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Horizon (HZNP) Inks Collaboration Deal with Q32 Bio for ADX-914
by Zacks Equity Research
Horizon (HZNP) enters into a collaboration and option agreement with Q32 Bio to develop the latter's ADX-914 for treating autoimmune diseases.
Does Atara Biotherapeutics (ATRA) Have the Potential to Rally 204% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Atara Biotherapeutics (ATRA) points to a 204.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe
by Zacks Equity Research
Seagen (SGEN) focuses on improving sales of its marketed drugs approved for different types of cancer indications. Stiff competition in the market remains a woe.
Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 65.93% and 483.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Immunovant (IMVT) Loss Narrows in Q1, Focus on Batoclimab
by Zacks Equity Research
Immunovant's (IMVT) earnings beat estimates in the fiscal first quarter ended on Jun 30, 2022. The company is evaluating batoclimab in a pivotal study for treating myasthenia gravis.
Deciphera (DCPH) Loss Narrows in Q2, Qinlock Drive Revenues
by Zacks Equity Research
Deciphera (DCPH) reports a narrower-than-expected loss in the second quarter of 2022 while revenues beat estimates. Shares rise.
Calyxt (CLXT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Calyxt (CLXT) delivered earnings and revenue surprises of 6.67% and 36.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Editas' (EDIT) Loss Narrows in Q2, Revenues Trump Estimates
by Zacks Equity Research
Editas (EDIT) reports a narrower-than-expected loss in the second quarter of 2022 while its revenues beat estimates. Focus remains on the lead candidate, EDIT-101.
Novo Nordisk's (NVO) Q2 Earnings Miss, Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) missed estimates for earnings in the second quarter of 2022 while revenues beat the same, driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
Horizon (HZNP) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Horizon's (HZNP) earnings and revenues lag estimates in the second quarter of 2022. The company lowers full-year revenue guidance for 2022. Shares were down in pre-market trading.
After Plunging 65.7% in 4 Weeks, Here's Why the Trend Might Reverse for Atara Biotherapeutics (ATRA)
by Zacks Equity Research
Atara Biotherapeutics (ATRA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Dr. Reddy's (RDY) Q1 Earnings Increase Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and sales increase year over year in first-quarter fiscal 2023.
Atara Biotherapeutics (ATRA) Moves 17% Higher: Will This Strength Last?
by Zacks Equity Research
Atara Biotherapeutics (ATRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 11.22% and 11.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Alkermes (ALKS) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 1,100% and 6.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Atara Biotherapeutics (ATRA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Atara Biotherapeutics (ATRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -60% and 84.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Atara Biotherapeutics (ATRA) This Earnings Season?
by Zacks Equity Research
Atara Biotherapeutics (ATRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics
by Zacks Equity Research
Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.
Biotech Stock Roundup: SAGE, ATRA Down on Study Updates, AGIO Drug Approval & More
by Zacks Equity Research
Updates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week.
Kodiak Sciences (KOD) Q3 Loss Widens, Eye Candidate in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports wider-than-expected loss for the third quarter of 2021. Pipeline development remains in focus for the company.
How Much Upside is Left in Atara Biotherapeutics (ATRA)? Wall Street Analysts Think 48%
by Zacks Equity Research
The consensus price target hints at a 48.3% upside potential for Atara Biotherapeutics (ATRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 2.17% and 1.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -3.41% and -38.77%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?